Reducing ICI dose frequency in cancer patients led to more deaths, prompting early trial termination and highlighting risks of less frequent dosing.

The combination of osimertinib and savolitinib improves survival in patients with EGFR-mutated NSCLC with MET alterations ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-low advanced breast cancer, regardless of ...

The novel antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) continues to show significant survival benefits for patients with EGFR mutated nonsquamous non-small cell lung cancer (NSCLC) ...

Darolutamide plus ADT and radiotherapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone.

Once again, a major clinical trial has shown that for patients with muscle invasive bladder cancer (MIBC) who were ineligible for or decline cisplatin-based chemotherapy before radical cystectomy, ...

The early promise of therapeutic gold seen in clinical trials of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd; Enhertu) for HER2-low, hormone receptor (HR)-positive early-stage ...